Figure 2.

Peripheral CGRP reduces motility. Motility was measured at the same time as light aversion with the same mice shown in Figure 1. A, Resting time in light and dark zones. After intraperitoneal injection, CGRP-treated mice (CD1, n = 19; C57BL/6J, n = 44) spent significantly more time resting in the dark zone compared with vehicle-treated mice (CD1, n = 19; C57BL/6J, n = 42) and compared with the Pre2 and Post periods. There were no significant differences in the light zone. B, Number of vertical beam breaks per minutes in light and dark zones. For both strains, CGRP treatment decreased the number of vertical beam breaks in the dark and to a lesser degree in the light. C, Number of transitions between the light and dark zones. For both strains, CGRP decreased transitions between zones, although to a greater degree with CD1 mice. For all panels, the mean ± SEM is shown, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.